PMID- 28244954
OWN - NLM
STAT- MEDLINE
DCOM- 20180109
LR  - 20211008
IS  - 1473-5571 (Electronic)
IS  - 0269-9370 (Print)
IS  - 0269-9370 (Linking)
VI  - 31
IP  - 8
DP  - 2017 May 15
TI  - Increased HIV-1 superinfection risk in carriers of specific human leukocyte 
      antigen alleles.
PG  - 1149-1158
LID - 10.1097/QAD.0000000000001445 [doi]
AB  - OBJECTIVE: The aim of this study was to characterize the demographic, 
      behavioural, clinical and immunogenetic determinants of HIV-1 superinfection in a 
      high-risk cohort of MSM. DESIGN: A retrospective cohort study of prospectively 
      followed MSM. METHODS: Ninety-eight MSM with acute or early HIV-1 monoinfection 
      were followed for a median of 15.6 months. Demographic and human leukocyte 
      antigen (HLA) genotype data were collected at enrolment. Sexual behaviour, 
      clinical and the infection status (monoinfection or superinfection) data were 
      recorded at each visit (at enrolment and thereafter at a median of 4.2-month 
      intervals). HIV-1 superinfection risk was determined by Cox regression and 
      Kaplan-Meier survival analysis. RESULTS: Ten individuals (10.2%) had 
      superinfection during follow-up. Cox regression did not show significantly 
      increased superinfection risk for individuals with an increased amount of 
      condomless anal intercourse, lower CD4 T-cell count or higher viral load, but 
      higher number of sexual contacts demonstrated a trend towards significance 
      [hazard ratio, 4.74; 95% confidence interval (95% CI), 0.87-25.97; P = 0.073]. 
      HLA-A*29 (hazard ratio, 4.10; 95% CI, 0.88-14.76; P = 0.069), HLA-B*35 (hazard 
      ratio, 4.64; 95% CI, 1.33-18.17; P = 0.017), HLA-C*04 (hazard ratio, 5.30; 95% 
      CI, 1.51-20.77; P = 0.010), HLA-C*16 (hazard ratio, 4.05; 95% CI, 0.87-14.62; 
      P = 0.071), HLA-DRB1*07 (hazard ratio, 3.29; 95% CI, 0.94-12.90; P = 0.062) and 
      HLA-DRB1*08 (hazard ratio, 15.37; 95% CI, 2.11-79.80; P = 0.011) were associated 
      with an increased risk of superinfection at alpha = 0.10, whereas HLA-DRB1*11 was 
      associated with decreased superinfection risk (hazard ratio, 0.13; 95% CI, 
      0.00-1.03; P = 0.054). CONCLUSION: HLA genes may, in part, elucidate the genetic 
      basis of differential superinfection risk, and provide important information for 
      the development of efficient prevention and treatment strategies of HIV-1 
      superinfection.
FAU - Vesa, Jouni
AU  - Vesa J
AD  - aUniversity of California San Diego, La Jolla bVeterans Affairs San Diego 
      Healthcare System, San Diego, California, USA.
FAU - Chaillon, Antoine
AU  - Chaillon A
FAU - Wagner, Gabriel A
AU  - Wagner GA
FAU - Anderson, Christy M
AU  - Anderson CM
FAU - Richman, Douglas D
AU  - Richman DD
FAU - Smith, Davey M
AU  - Smith DM
FAU - Little, Susan J
AU  - Little SJ
LA  - eng
GR  - K23 MH105231/MH/NIMH NIH HHS/United States
GR  - U01 AI043638/AI/NIAID NIH HHS/United States
GR  - P30 MH062512/MH/NIMH NIH HHS/United States
GR  - P30 AI036214/AI/NIAID NIH HHS/United States
GR  - R24 AI106039/AI/NIAID NIH HHS/United States
GR  - P01 AI074621/AI/NIAID NIH HHS/United States
GR  - R01 MH100974/MH/NIMH NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - AIDS
JT  - AIDS (London, England)
JID - 8710219
RN  - 0 (HLA Antigens)
SB  - IM
MH  - Adult
MH  - *Alleles
MH  - Follow-Up Studies
MH  - HIV Infections/*epidemiology/*immunology
MH  - HLA Antigens/*genetics
MH  - Homosexuality, Male
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Risk Assessment
MH  - Superinfection/*epidemiology
MH  - Young Adult
PMC - PMC5559224
MID - NIHMS888311
COIS- Conflicts of interest D.D.R. has served as a consultant for Chimerix, Gilead 
      Sciences and Monogram Biosciences. D.M.S. has served as a consultant for 
      Gen-Probe and Testing Talent Services, and has received research funding from 
      ViiV Pharmaceuticals. S.J.L. has received research grant funding from Gilead 
      Sciences.
EDAT- 2017/03/01 06:00
MHDA- 2018/01/10 06:00
PMCR- 2018/05/15
CRDT- 2017/03/01 06:00
PHST- 2017/03/01 06:00 [pubmed]
PHST- 2018/01/10 06:00 [medline]
PHST- 2017/03/01 06:00 [entrez]
PHST- 2018/05/15 00:00 [pmc-release]
AID - 10.1097/QAD.0000000000001445 [doi]
PST - ppublish
SO  - AIDS. 2017 May 15;31(8):1149-1158. doi: 10.1097/QAD.0000000000001445.